<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Skin Cancer Detection &amp; Diagnosis Archives - MoleMax Systems</title>
	<atom:link href="https://molemaxsystems.com/category/skin-cancer-detection-diagnosis/feed/" rel="self" type="application/rss+xml" />
	<link>https://molemaxsystems.com/category/skin-cancer-detection-diagnosis/</link>
	<description>Provide the best skin imaging device</description>
	<lastBuildDate>Fri, 02 Oct 2026 07:05:50 +0000</lastBuildDate>
	<language>en-AU</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	

<image>
	<url>https://molemaxsystems.com/wp-content/uploads/2020/10/favicon.png</url>
	<title>Skin Cancer Detection &amp; Diagnosis Archives - MoleMax Systems</title>
	<link>https://molemaxsystems.com/category/skin-cancer-detection-diagnosis/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Eccrine Poroma Dermoscopy: Features, Patterns &#038; Diagnosis </title>
		<link>https://molemaxsystems.com/eccrine-poroma-dermoscopy/</link>
		
		<dc:creator><![CDATA[keshab]]></dc:creator>
		<pubDate>Fri, 02 Oct 2026 06:52:18 +0000</pubDate>
				<category><![CDATA[Skin Cancer Detection & Diagnosis]]></category>
		<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[amelanotic melanoma]]></category>
		<category><![CDATA[basal cell carcinoma]]></category>
		<category><![CDATA[dermatoscope]]></category>
		<category><![CDATA[DermLite]]></category>
		<category><![CDATA[differential diagnosis]]></category>
		<category><![CDATA[eccrine poroma]]></category>
		<category><![CDATA[pigmented poroma]]></category>
		<category><![CDATA[polymorphous vessels]]></category>
		<category><![CDATA[poroma dermoscopy]]></category>
		<category><![CDATA[vascular pattern]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=12131</guid>

					<description><![CDATA[<p>A clinical guide to eccrine poroma dermoscopy vascular patterns, key features, and how to tell it apart from melanoma.</p>
<p>The post <a href="https://molemaxsystems.com/eccrine-poroma-dermoscopy/">Eccrine Poroma Dermoscopy: Features, Patterns &#038; Diagnosis </a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">Eccrine poroma is benign, but it is one of dermatology&#8217;s most convincing imitators  clinically, it can pass for basal cell carcinoma, pyogenic granuloma, or amelanotic melanoma. Dermoscopy is what separates these at the bedside: the vascular and structural clues it reveals are invisible to the naked eye. This guide covers the dermoscopic features of eccrine poroma, how to examine it correctly, its differential diagnosis, and when imaging should prompt a biopsy rather than reassurance. </p>



<h2 class="wp-block-heading"><strong>At a Glance</strong> </h2>



<p class="wp-block-paragraph"><strong>Quick answer:</strong> Eccrine poroma dermoscopy shows a polymorphous vascular pattern  glomerular, hairpin, and linear-irregular vessels together surrounded by milky-red to white structureless areas and white interlacing haloes. No single feature confirms the diagnosis; it is the combination, read alongside the clinical picture, that distinguishes poroma from BCC, pyogenic granuloma, and amelanotic melanoma. </p>



<h2 class="wp-block-heading"><strong>What Is an Eccrine Poroma?</strong> </h2>



<p class="wp-block-paragraph">An eccrine poroma is a benign adnexal tumour arising from the terminal portion of the sweat-gland duct. It typically presents as a solitary, slow-growing, pink-to-red papule or nodule, most often on the palms, soles, or lower limbs, though it can occur anywhere on the body. Lesions are usually asymptomatic but may bleed easily or feel tender when knocked. </p>



<p class="wp-block-paragraph">Because poromas are predominantly non-pigmented and vascular, they are easily mistaken for other pink lesions, both benign and malignant. That ambiguity is exactly where dermoscopy earns its place: it gives the practitioner objective structural information rather than a judgement based on colour and shape alone. </p>



<h2 class="wp-block-heading"><strong>How to Examine a Suspected Poroma</strong> </h2>



<p class="wp-block-paragraph">A reliable read starts with technique. Both polarised and non-polarised dermoscopy add value: polarised light shows vascular structures and deeper features more clearly, while non-polarised light with contact fluid highlights surface detail. Apply minimal pressure vascular lesions like poroma blanch easily, and their vessels can disappear if the instrument is pressed too firmly, taking the diagnostic information with them. </p>



<p class="wp-block-paragraph">A quality dermatoscope from the <a href="https://molemaxsystems.com/product-category/dermlite/dermatoscopes/" target="_blank" rel="noopener">DermLite range</a> makes it straightforward to switch between polarised and non-polarised modes on the same lesion; examining in both modes routinely surfaces features that a single view can miss. </p>



<h2 class="wp-block-heading"><strong>Dermoscopic Features of Eccrine Poroma</strong> </h2>



<p class="wp-block-paragraph">No single feature is pathognomonic, but several patterns recur and, taken together, point towards the diagnosis. Dermoscopedia lists branched vessels with rounded endings, white interlacing areas, yellow structureless areas, and milky-red globules as the core associated features. </p>



<figure class="wp-block-table">
<table class="has-fixed-layout">
<tbody>
<tr>
<td><strong>Feature</strong> </td>
<td><strong>Appearance</strong> </td>
<td><strong>Diagnostic note</strong> </td>
</tr>
<tr>
<td>Polymorphous vascular pattern </td>
<td>Glomerular (coiled), hairpin, and linear-irregular vessels within one lesion </td>
<td>One of the most consistent and useful clues </td>
</tr>
<tr>
<td>Milky-red / &#8220;cherry-blossom&#8221; areas </td>
<td>Pink-white to milky-red structureless zones surrounding the vessels </td>
<td>Reflects the tumour&#8217;s rich blood supply and oedematous stroma </td>
</tr>
<tr>
<td>White interlacing areas and haloes </td>
<td>Pale, white, interlacing bands or haloes around vessels </td>
<td>Helps distinguish poroma from purely malignant vascular lesions </td>
</tr>
<tr>
<td>Yellowish structureless zones </td>
<td>Yellow, structureless areas with a well-demarcated border </td>
<td>Corresponds to the tumour&#8217;s histological architecture </td>
</tr>
</tbody>
</table>
</figure>



<p class="wp-block-paragraph">These patterns are documented in detail by Lallas et al. in their widely cited paper, <em>&#8220;Eccrine poroma: the great dermoscopic imitator&#8221;</em> (<em>J Eur Acad Dermatol Venereol</em>, 2016) a useful reference when building a mental image library for these lesions. </p>



<h3 class="wp-block-heading"><strong>Why Vascular Patterns Matter More Than Pigment</strong> </h3>



<p class="wp-block-paragraph">Because poromas are non-pigmented far more often than not, the usual pigment-based melanoma criteria offer little help here. The diagnosis instead rests on reading vessel morphology and distribution which is why a careful, low-pressure examination under polarised light matters so much. Training the eye to distinguish glomerular from hairpin from arborising vessels is the single most valuable skill for assessing these lesions. </p>



<p class="wp-block-paragraph">The dermoscopic patterns are not arbitrary: they mirror the underlying histology. The rich, polymorphous vessels correspond to the tumour&#8217;s prominent vascular stroma, while the milky-red and white areas reflect its characteristic cellular islands and surrounding tissue. Understanding this correlation builds confidence in reading the image, and explains why a poroma looks so vascular under the dermatoscope in the first place. </p>



<p class="wp-block-paragraph"><strong>Vessel types at a glance:</strong> </p>



<figure class="wp-block-table">
<table class="has-fixed-layout">
<tbody>
<tr>
<td><strong>Vessel pattern</strong> </td>
<td><strong>What it looks like</strong> </td>
</tr>
<tr>
<td>Glomerular </td>
<td>Tightly coiled, ball-like vessels </td>
</tr>
<tr>
<td>Hairpin </td>
<td>Looped vessels with a U-turn, often with a white halo </td>
</tr>
<tr>
<td>Linear-irregular </td>
<td>Straight or slightly curved vessels of uneven calibre </td>
</tr>
<tr>
<td>Arborising (BCC clue, not poroma) </td>
<td>Branching, tree-like vessels with decreasing calibre </td>
</tr>
</tbody>
</table>
</figure>



<h2 class="wp-block-heading"><strong>Differential Diagnosis and When to Biopsy</strong> </h2>



<h3 class="wp-block-heading"><strong>What Poroma Can Mimic</strong> </h3>



<p class="wp-block-paragraph">The reason clinicians reach for the dermatoscope is that a poroma can imitate lesions with very different implications. </p>



<figure class="wp-block-table">
<table class="has-fixed-layout">
<tbody>
<tr>
<td><strong>Mimic</strong> </td>
<td><strong>Distinguishing dermoscopic clue</strong> </td>
</tr>
<tr>
<td>Basal cell carcinoma </td>
<td>Classically shows arborising vessels and other BCC-specific structures, rather than poroma&#8217;s polymorphous mix </td>
</tr>
<tr>
<td>Amelanotic melanoma (critical exclusion) </td>
<td>May show atypical polymorphous vessels; demands a low threshold for biopsy whenever present </td>
</tr>
<tr>
<td>Pyogenic granuloma </td>
<td>Often a single dominant vascular pattern rather than poroma&#8217;s polymorphous mix, with a collarette and rapid growth history </td>
</tr>
<tr>
<td>Squamous cell carcinoma </td>
<td>Looks for keratin, white circles, and different vessel morphology against a background of sun damage </td>
</tr>
<tr>
<td>Irritated seborrhoeic keratosis </td>
<td>Comedo-like openings and milia-like cysts typical of keratosis, rather than a vascular-dominant picture </td>
</tr>
</tbody>
</table>
</figure>



<p class="wp-block-paragraph">When malignancy cannot be confidently excluded, structured criteria such as those in our <a href="https://molemaxsystems.com/7-point-checklist-for-melanoma-a-complete-dermoscopy/" target="_blank" rel="noopener">7-Point Checklist for Melanoma</a> and prompt histology remain essential. Dermoscopy narrows the differential; it does not eliminate the need for biopsy in genuinely uncertain lesions. </p>



<h3 class="wp-block-heading"><strong>When to Biopsy</strong> </h3>



<p class="wp-block-paragraph">A practical rule: dermoscopy should increase, never replace, clinical caution. If a lesion shows classic poroma features and a benign history, monitoring with documented imaging is reasonable. But any lesion with atypical vessels, rapid change, ulceration, or an uncertain read warrants excision and histology. Because amelanotic melanoma sits in this differential, erring toward biopsy when in doubt is the safe course. </p>



<h2 class="wp-block-heading"><strong>Documenting a Poroma for Follow-Up</strong> </h2>



<p class="wp-block-paragraph">For a lesion as ambiguous as poroma, documentation is as valuable as the initial read. A handheld dermatoscope from the DermLite range gives the magnified, polarised view needed to assess vascular patterns, while a digital system such as the <a href="https://molemaxsystems.com/product-molemax-hd/" target="_blank" rel="noopener">MoleMax HD</a> captures and stores that image so the lesion can be monitored, compared over time, or reviewed by a colleague. Recording the dermoscopic appearance also strengthens the clinical record if the lesion later changes or is excised. </p>



<h2 class="wp-block-heading"><strong>Poroma&#8217;s Clinical Spectrum</strong> </h2>



<h3 class="wp-block-heading"><strong>The Poroid Tumour Family</strong> </h3>



<p class="wp-block-paragraph">Poroma is not a single, uniform entity. It belongs to a family of poroid tumours that also includes hidroacanthoma simplex, dermal duct tumour, and poroid hidradenoma, each with its own histological emphasis but overlapping clinical and dermoscopic features. Recognising that these variants exist helps explain why the dermoscopic picture can vary from one lesion to the next, and why the diagnosis is ultimately confirmed on histology rather than on dermoscopy alone. </p>



<h3 class="wp-block-heading"><strong>Pigmented Poroma: A Diagnostic Trap</strong> </h3>



<p class="wp-block-paragraph">Most poromas are pink and vascular, but a minority are pigmented observational studies report pigmentation in roughly 17% of cases. These darker lesions are the most treacherous, because they can closely resemble melanoma or pigmented basal cell carcinoma on both clinical and dermoscopic examination. Pigmented poromas may show blue-grey or brown structures alongside the usual vascular patterns, and this combination should lower the clinician&#8217;s threshold for biopsy considerably. When pigment enters the picture, the safest assumption is that the lesion needs histological confirmation. </p>



<p class="wp-block-paragraph">This is a good example of why dermoscopy is best understood as a triage tool. It sorts lesions into &#8220;confidently benign,&#8221; &#8220;confidently in need of excision,&#8221; and &#8220;uncertain&#8221; and it is the uncertain group, where pigmented poroma often sits, that benefits most from documented imaging and specialist review. </p>



<h2 class="wp-block-heading"><strong>Key Takeaways</strong> </h2>



<ul class="wp-block-list">
<li>Eccrine poroma is benign but a frequent mimic of malignant lesions, so it deserves careful assessment. </li>
</ul>



<ul class="wp-block-list">
<li>A polymorphous vascular pattern, milky-red areas, and white haloes are the most useful dermoscopic clues none is definitive alone. </li>
</ul>



<ul class="wp-block-list">
<li>The critical exclusions are amelanotic melanoma and basal cell carcinoma. </li>
</ul>



<ul class="wp-block-list">
<li>Any atypical, pigmented, ulcerated, or rapidly changing lesion should be biopsied. </li>
</ul>



<ul class="wp-block-list">
<li>Dermoscopy should sharpen clinical judgement, not override it; documenting the lesion with digital imaging protects both patient and practitioner over time. </li>
</ul>



<p class="wp-block-paragraph">For clinicians building their dermoscopy skills, poroma is a useful teaching lesion precisely because it forces attention onto vascular reading rather than pigment a skill that pays off across the whole spectrum of non-pigmented tumours. Dermoscopedia and DermNet offer extensive image libraries for comparison as you develop that eye. </p>



<h2 class="wp-block-heading"><strong>Frequently Asked Questions</strong> </h2>



<p class="wp-block-paragraph"><strong>What is poroma dermatoscopia (poroma dermoscopy)?</strong>  </p>



<p class="wp-block-paragraph">It&#8217;s the dermoscopic examination of an eccrine poroma using a dermatoscope to reveal the lesion&#8217;s vascular pattern and surface structures, which are not visible to the naked eye and help distinguish it from malignant look-alikes. </p>



<p class="wp-block-paragraph"><strong>Is poroma ecrino the same as eccrine poroma?</strong>  </p>



<p class="wp-block-paragraph">Yes, <em>poroma ecrino</em> is the Spanish term for eccrine poroma, a benign tumour of the sweat-gland duct. </p>



<p class="wp-block-paragraph"><strong>Can dermoscopy alone confirm eccrine poroma?</strong>  </p>



<p class="wp-block-paragraph">No. Dermoscopy narrows the differential and raises or lowers suspicion, but histology is required for definitive diagnosis, particularly when any atypical or pigmented feature is present. </p>



<p class="wp-block-paragraph"><strong>What is the most important feature to rule out on dermoscopy?</strong>  </p>



<p class="wp-block-paragraph">Ruling out amelanotic melanoma is the priority atypical polymorphous vessels or any diagnostic uncertainty should lower the threshold for biopsy. </p>



<p class="wp-block-paragraph"><strong>Are all eccrine poromas pink?</strong> No. Most are pink and vascular, but pigmented variants occur in roughly 17% of cases and carry a higher risk of being mistaken for melanoma or pigmented basal cell carcinoma. </p>



<h2 class="wp-block-heading"><strong>See Dermoscopic Imaging in Practice</strong> </h2>



<p class="wp-block-paragraph"><a href="https://molemaxsystems.com/online-demo-request" target="_blank" rel="noopener">Book a free 15-minute MoleMax demo</a> and our specialist team will show you high-resolution capture, lesion tracking, side-by-side comparison, and structured reporting on real cases — and answer any questions specific to your practice. </p>



<p class="wp-block-paragraph">&nbsp;</p>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/clinical-workflow-documentation/">CLINICAL WORKFLOW &AMP; DOCUMENTATION</a></li><li><a href="https://molemaxsystems.com/category/dermoscopy-techniques-clinical-studies/">DERMOSCOPY TECHNIQUES &AMP; CLINICAL STUDIES</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/molemax-hd-total-body-mapping/">MOLEMAX HD &AMP; TOTAL BODY MAPPING</a></li><li><a href="https://molemaxsystems.com/category/research-clinical-evidence/">RESEARCH &AMP; CLINICAL EVIDENCE</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-detection-diagnosis/">SKIN CANCER DETECTION &AMP; DIAGNOSIS</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-research-evidence/">SKIN CANCER RESEARCH &AMP; EVIDENCE</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/eccrine-poroma-dermoscopy/">Eccrine Poroma Dermoscopy: Features, Patterns &#038; Diagnosis </a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Clinical and Dermoscopic Characterization of Mixed-Type Basal Cell Carcinoma</title>
		<link>https://molemaxsystems.com/clinical-and-dermoscopic-characterization-of-mixed-type-basal-cell-carcinoma/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Tue, 04 Aug 2026 02:25:07 +0000</pubDate>
				<category><![CDATA[Skin Cancer Detection & Diagnosis]]></category>
		<category><![CDATA[skin cancer]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=10551</guid>

					<description><![CDATA[<p>Explore the clinical and dermoscopic features of mixed-type basal cell carcinoma and how subtype patterns may support diagnosis and treatment decisions.</p>
<p>The post <a href="https://molemaxsystems.com/clinical-and-dermoscopic-characterization-of-mixed-type-basal-cell-carcinoma/">Clinical and Dermoscopic Characterization of Mixed-Type Basal Cell Carcinoma</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div id="fws_6abfc0c813b52"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row top-level"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<p>Fethi Zaid, Kerem Balan, Gonca Elçin, Özay Gokoz , Duygu Gülseren</p>
<p>Department of Dermatology and Venereology, Hacettepe University Faculty of Medicine, Ankara, Turkey<br />
Department of Medical Pathology, Hacettepe University Faculty of Medicine, Ankara, Turkey</p>
</div>




			</div> 
		</div>
	</div> 
</div></div>
		<div id="fws_6abfc0c81502a"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<p><strong>Introduction</strong>: Basal cell carcinoma (BCC) is a malignant skin tumor that originates from epidermal basal cells or the outer root sheath of hair follicles. Identifying histopathological subtypes is crucial to guiding treatment and patient follow-up. While dermoscopic features associated with histopatho-logical subtypes have been studied, the changes in dermoscopic findings in mixed-type BCC remain unclear.</p>
<p><strong>Objectives</strong>: This study aimed to analyze the demographic characteristics of patients diagnosed with single and mixed-type BCC and to investigate the correlation between clinical and dermoscopic findings and histopathological subtypes.</p>
<p><strong>Results</strong>: A total of 186 BCC lesions from 157 patients were analyzed. The mean patient age was 68.8±12.7 years (range: 30–94). The most common lesion location was the head and neck region (74.7%). The distribution of histopathological subtypes was as follows: nodular (42.5%), mixed-type (37.6%), superficial (12.4%), basosquamous (3.2%), infiltrative (2.7%), micronodular (1.1%), and fibroepithelial (0.5%). The most frequent mixed-type BCC combinations were nodular-infiltrative (32.9%), nodular-superficial (31.4%), and nodular-micronodular (12.9%).</p>
<p>Short fine telangiectasia, yellow-white structureless areas, scales, and rosette structures were more frequent in mixed-type BCC. Corkscrew vessel patterns were more common in single-type lesions. The presence of a superficial component in mixed-type BCC was associated with wheel-like structures, while infiltrative components correlated with dotted and glomerular vessel patterns, and basosqua- mous components were linked to arborizing vessel patterns. Additionally, arborizing vessel patterns (P=0.019) and dotted vessel patterns (P=0.025) were associated with high-risk subtypes in mixed-type BCC.</p>
<p><strong>Conclusion</strong>: Our study suggests that dermoscopic findings may serve as a guide to recognizing mixed-type BCC lesions, distinguishing between subtype components, and assisting in treatment decision-making based on these observations.</p>
<p>To read the full article please <a href="https://dpcj.org/index.php/dpc/article/view/6489/3826" target="_blank" rel="noopener">click here</a>.</p>
</div>




			</div> 
		</div>
	</div> 
</div></div>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/clinical-workflow-documentation/">CLINICAL WORKFLOW &AMP; DOCUMENTATION</a></li><li><a href="https://molemaxsystems.com/category/dermoscopy-techniques-clinical-studies/">DERMOSCOPY TECHNIQUES &AMP; CLINICAL STUDIES</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/molemax-hd-total-body-mapping/">MOLEMAX HD &AMP; TOTAL BODY MAPPING</a></li><li><a href="https://molemaxsystems.com/category/research-clinical-evidence/">RESEARCH &AMP; CLINICAL EVIDENCE</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-detection-diagnosis/">SKIN CANCER DETECTION &AMP; DIAGNOSIS</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-research-evidence/">SKIN CANCER RESEARCH &AMP; EVIDENCE</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/clinical-and-dermoscopic-characterization-of-mixed-type-basal-cell-carcinoma/">Clinical and Dermoscopic Characterization of Mixed-Type Basal Cell Carcinoma</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Diagnostic Accuracy of Dermoscopic Features in Acral Lentiginous Melanoma</title>
		<link>https://molemaxsystems.com/diagnostic-accuracy-of-dermoscopic-features-in-acral-lentiginous-melanoma/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Tue, 07 Jul 2026 05:26:07 +0000</pubDate>
				<category><![CDATA[Skin Cancer Detection & Diagnosis]]></category>
		<category><![CDATA[Acral Lentiginous Melanoma]]></category>
		<category><![CDATA[skin cancer]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=10104</guid>

					<description><![CDATA[<p>Review which dermoscopic features best distinguish acral lentiginous melanoma from benign acral nevi and support earlier, standardised diagnosis.</p>
<p>The post <a href="https://molemaxsystems.com/diagnostic-accuracy-of-dermoscopic-features-in-acral-lentiginous-melanoma/">Diagnostic Accuracy of Dermoscopic Features in Acral Lentiginous Melanoma</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div id="fws_6abfc0c817673"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<nav role="none"><span class="wi-fullname brand-fg">Chidimma J. Okwara, MD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">T. Austin Black, BS</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Priscilla L. Haff, BS; </span><span class="wi-fullname brand-fg">Helena M. Nammour, BS, BA</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Roland Bassett, MS</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">John Das, MD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Justin H. Qian, MD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Hayden P. Schandua, BS</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Anthony J. Teixeira, BA</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Nadeen Gonna, MD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Areebah S. Ahmad, BS</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Chidi M. Okoro, BS</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">David P. Farris, MSIS, AHIP</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Kelly C. Nelson, MD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Hung Q. Doan, MD, PHD</span> </nav>
<nav role="none"></nav>
<h3 role="none"><strong><br />
A Systematic Review and Meta-Analysis</strong></h3>
<h3><strong><br />
<span style="text-decoration: underline;">Key Points</span></strong></h3>
<p><strong><br />
Question</strong>  Which dermoscopic features most reliably distinguish acral lentiginous melanoma from benign acral nevi?</p>
<p><strong>Finding  </strong>In this systematic review and meta-analysis of 41 studies that included 8845 nevi and 801 melanomas, the parallel ridge and multicomponent features were statistically associated with acral lentiginous melanoma, whereas the parallel furrow and latticelike features were significantly associated with benign acral lesions.</p>
<p><strong>Meaning</strong>  Beyond the previously established ridge and furrow criteria, this systematic review and meta-analysis demonstrates the diagnostic relevance of multicomponent and latticelike features, supporting earlier detection and the standardization of dermoscopic evaluation of acral lesions.</p>
<p>To read further on this article please <a href="https://jamanetwork.com/journals/jamadermatology/article-abstract/2845625?guestAccessKey=1c737cd9-d8df-4954-a862-f24238b79e69&amp;utm_medium=email&amp;utm_source=postup_jn&amp;utm_campaign=article_alert-jamadermatology&amp;utm_content=etoc-tfl_&amp;utm_term=052126" target="_blank" rel="noopener">click here</a>.</p>
<nav role="none"></nav>
</div>




			</div> 
		</div>
	</div> 
</div></div>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/clinical-workflow-documentation/">CLINICAL WORKFLOW &AMP; DOCUMENTATION</a></li><li><a href="https://molemaxsystems.com/category/dermoscopy-techniques-clinical-studies/">DERMOSCOPY TECHNIQUES &AMP; CLINICAL STUDIES</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/molemax-hd-total-body-mapping/">MOLEMAX HD &AMP; TOTAL BODY MAPPING</a></li><li><a href="https://molemaxsystems.com/category/research-clinical-evidence/">RESEARCH &AMP; CLINICAL EVIDENCE</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-detection-diagnosis/">SKIN CANCER DETECTION &AMP; DIAGNOSIS</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-research-evidence/">SKIN CANCER RESEARCH &AMP; EVIDENCE</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/diagnostic-accuracy-of-dermoscopic-features-in-acral-lentiginous-melanoma/">Diagnostic Accuracy of Dermoscopic Features in Acral Lentiginous Melanoma</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Limits of Artificial Intelligence Models for Skin Cancer Diagnosis in Realistic Settings</title>
		<link>https://molemaxsystems.com/limits-of-artificial-intelligence-models-for-skin-cancer-diagnosis-in-realistic-settings/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Tue, 23 Jun 2026 05:03:13 +0000</pubDate>
				<category><![CDATA[Skin Cancer Detection & Diagnosis]]></category>
		<category><![CDATA[dematology research]]></category>
		<category><![CDATA[skin cancer]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=10065</guid>

					<description><![CDATA[<p>How does artificial intelligence (AI) diagnostic performance compare to human dermatologists of varying experience for skin cancer detection in realistic clinical settings?</p>
<p>The post <a href="https://molemaxsystems.com/limits-of-artificial-intelligence-models-for-skin-cancer-diagnosis-in-realistic-settings/">Limits of Artificial Intelligence Models for Skin Cancer Diagnosis in Realistic Settings</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div id="fws_6abfc0c81ac85"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<nav role="none"><span class="wi-fullname brand-fg">Julien Anriot, MD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Siyuan Yan, PhD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Clio Coste, MD, PhD; </span><span class="wi-fullname brand-fg">Philipp Tschandl, MD, PhD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Loic Verlingue, MD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Camille Andremasse, MD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Mona Amini-Adle, MD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Jean Luc Perrot, MD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Zongyuan Ge, PhD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Harald Kittler, MD, PhD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Luc Thomas, MD, PhD</span></nav>
<h3><span class="heading-text thm-col h3 cb section-type-keyPoints decorated-hed sb-sc "><br />
<strong>Key Points</strong></span></h3>
<p><strong>Question</strong>  How does artificial intelligence (AI) diagnostic performance compare to human dermatologists of varying experience for skin cancer detection in realistic clinical settings?</p>
<p><strong>Findings</strong>  In this diagnostic study of 652 physicians and 3 AI models evaluating 1117 cases, expert dermatologists (&gt;10 years of experience) achieved the highest accuracy (74.2%), considerably outperforming a modern unimodal foundation model (72.2%), which exceeded dermatologists with less than 1 year of experience (59.1%), while the first-generation convolutional neural network underperformed all readers (56.7%).</p>
<p><strong>Meaning</strong>  Future practice should integrate human-AI collaboration, with AI supporting less experienced clinicians and providing expert triage assistance and help to minimize fatigue-related diagnostic errors.</p>
<p>To read further on this article please <a href="https://jamanetwork.com/journals/jamadermatology/fullarticle/2849416?guestAccessKey=0150ca00-9e91-4991-91bc-c92587ac78fb&amp;utm_medium=email&amp;utm_source=postup_jn&amp;utm_campaign=article_alert-jamadermatology&amp;utm_content=olf-recommended-tfl_&amp;utm_term=061726" target="_blank" rel="noopener">click here</a>.</p>
</div>




			</div> 
		</div>
	</div> 
</div></div>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/clinical-workflow-documentation/">CLINICAL WORKFLOW &AMP; DOCUMENTATION</a></li><li><a href="https://molemaxsystems.com/category/dermoscopy-techniques-clinical-studies/">DERMOSCOPY TECHNIQUES &AMP; CLINICAL STUDIES</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/molemax-hd-total-body-mapping/">MOLEMAX HD &AMP; TOTAL BODY MAPPING</a></li><li><a href="https://molemaxsystems.com/category/research-clinical-evidence/">RESEARCH &AMP; CLINICAL EVIDENCE</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-detection-diagnosis/">SKIN CANCER DETECTION &AMP; DIAGNOSIS</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-research-evidence/">SKIN CANCER RESEARCH &AMP; EVIDENCE</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/limits-of-artificial-intelligence-models-for-skin-cancer-diagnosis-in-realistic-settings/">Limits of Artificial Intelligence Models for Skin Cancer Diagnosis in Realistic Settings</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Clinical and Pathologic Factors in Stage I and II Melanoma Recurrence</title>
		<link>https://molemaxsystems.com/clinical-and-pathologic-factors-in-stage-i-and-ii-melanoma-recurrence/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Tue, 28 Apr 2026 04:58:45 +0000</pubDate>
				<category><![CDATA[Skin Cancer Detection & Diagnosis]]></category>
		<category><![CDATA[melanoma]]></category>
		<category><![CDATA[skin cancer]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=9638</guid>

					<description><![CDATA[<p>Key factors influencing recurrence in early-stage melanoma</p>
<p>The post <a href="https://molemaxsystems.com/clinical-and-pathologic-factors-in-stage-i-and-ii-melanoma-recurrence/">Clinical and Pathologic Factors in Stage I and II Melanoma Recurrence</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div id="fws_6abfc0c81d92d"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<p><span style="color: #000000;"><span class="wi-fullname brand-fg">Maya Mundada, BS</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Xiaochen Zhong, BA</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Alexandra So, BS; </span><a class="meta-authors--etal td-u stats-meta-authors--etal" style="color: #000000;" tabindex="0" aria-label="et al"><span aria-hidden="true">et al</span></a></span></p>
</div>




<div class="wpb_text_column wpb_content_element " >
	<h3><strong><span style="text-decoration: underline;">Key Points</span></strong></h3>
<p>&nbsp;</p>
<p><strong>Question</strong>  What demographic, clinical, and pathological characteristics are associated with the time to recurrence of localized melanomas?</p>
<p><strong>Findings</strong>  In this cohort study of 1092 individuals diagnosed with stage IA to IIC melanomas, tumor ulceration, thickness, location on the face or scalp or neck compared with the arms, neurotropism, lymphovascular invasion, and presence of mitoses were associated with time to melanoma recurrence in multivariable analysis.</p>
<p><strong>Meaning</strong>  Results of this study suggest that factors in addition to melanoma ulceration and thickness provide an important guide for patient surveillance and counseling about potential recurrence.</p>
<p>To read more on this article please <a href="https://jamanetwork.com/journals/jamadermatology/article-abstract/2845561?guestAccessKey=9161d274-2282-48bd-9ffc-a83fd3d060c7&amp;utm_medium=email&amp;utm_source=postup_jn&amp;utm_campaign=article_alert-jamadermatology&amp;utm_content=etoc-tfl_&amp;utm_term=041626" target="_blank" rel="noopener">click here</a>.</p>
</div>




			</div> 
		</div>
	</div> 
</div></div>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/clinical-workflow-documentation/">CLINICAL WORKFLOW &AMP; DOCUMENTATION</a></li><li><a href="https://molemaxsystems.com/category/dermoscopy-techniques-clinical-studies/">DERMOSCOPY TECHNIQUES &AMP; CLINICAL STUDIES</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/molemax-hd-total-body-mapping/">MOLEMAX HD &AMP; TOTAL BODY MAPPING</a></li><li><a href="https://molemaxsystems.com/category/research-clinical-evidence/">RESEARCH &AMP; CLINICAL EVIDENCE</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-detection-diagnosis/">SKIN CANCER DETECTION &AMP; DIAGNOSIS</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-research-evidence/">SKIN CANCER RESEARCH &AMP; EVIDENCE</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/clinical-and-pathologic-factors-in-stage-i-and-ii-melanoma-recurrence/">Clinical and Pathologic Factors in Stage I and II Melanoma Recurrence</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Local Recurrence and Survival in Patients With Melanoma In Situ</title>
		<link>https://molemaxsystems.com/local-recurrence-and-survival-in-patients-with-melanoma-in-situ/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Tue, 11 Nov 2025 04:23:11 +0000</pubDate>
				<category><![CDATA[Skin Cancer Detection & Diagnosis]]></category>
		<category><![CDATA[dematology research]]></category>
		<category><![CDATA[melanoma]]></category>
		<category><![CDATA[skin cancer]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=8662</guid>

					<description><![CDATA[<p>Melanoma in situ recurrence and survival outcomes explored</p>
<p>The post <a href="https://molemaxsystems.com/local-recurrence-and-survival-in-patients-with-melanoma-in-situ/">Local Recurrence and Survival in Patients With Melanoma In Situ</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div id="fws_6abfc0c820266"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone "  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element " >
	<p><span class="authors-list-item ">Clio Dessinioti<span class="comma">, </span></span><span class="authors-list-item ">Aggeliki Befon<span class="comma">, </span></span><span class="authors-list-item ">Mihaella Plaka<span class="comma">, </span></span><span class="authors-list-item ">Aikaterini Niforou<span class="comma">, </span></span><span class="authors-list-item ">Katerina Kypreou<span class="comma">, </span></span><span class="authors-list-item ">Alan C Geller<span class="comma">, </span></span><span class="authors-list-item ">Alexander J Stratigos</span></p>
<h2 class="title">Abstract</h2>
<div id="eng-abstract" class="abstract-content selected">
<p><strong class="sub-title">Importance: </strong>The overdiagnosis of melanoma in situ (MIS) is well documented. There is limited evidence on the rate of local recurrence of the non-lentigo maligna (non-LM)/non-acral lentiginous melanoma (non-ALM) subtypes.</p>
<p><strong class="sub-title">Objective: </strong>To investigate local recurrence and prognosis in non-LM/non-ALM MIS, the histopathological clearance of the excisional biopsy margins, and the association with the size of wide excision margins.</p>
<p><strong class="sub-title">Design, setting, and participants: </strong>This retrospective cohort study included patients with non-LM/non-ALM MIS diagnosed from 1991 to 2023 who were followed up for at least 1 year at the Skin Cancer and Melanoma Unit of Andreas Sygros University Hospital in Athens, Greece. Patients with a history of invasive melanoma or a histopathological diagnosis of LM or ALM in situ were excluded. Median (IQR) follow-up was 5.2 (2.9-7.9) years. Deidentified data on patient demographics and clinical characteristics, including the histopathological clearance of margins of the initial excisional biopsy and the size of margins of the wide excision, were obtained from medical records.</p>
<p><strong class="sub-title">Main outcomes and measures: </strong>The primary outcomes were local recurrence, metastasis, and melanoma-specific survival.</p>
<p><strong class="sub-title">Results: </strong>A total of 401 patients (214 [53.4%] women) with 403 non-LM/non-ALM MIS and a median (IQR) age of 52 (40-62) years were included in the analysis. MIS was frequently located on the trunk (201 lesions [49.9%]), followed by the lower extremity (99 [24.6%]), the upper extremity (71 [17.6%]), and the head and neck (32 [7.9%]). All lesions were initially treated with excisional biopsy, followed by wide excision for 372 (92.3%). There was only 1 local recurrence in a patient with involved margins at the excisional biopsy who did not undergo wide excision and developed an invasive melanoma 14 months later. Thirty lesions in 30 patients had clear excisional biopsy margins with no wide excision and had no recurrence at a median (IQR) follow-up of 8.1 (4.1-12.9) years. In 23 patients with 23 lesions that had wide excision with narrower than the standard 0.5-cm margins (mean [SD] margin size, 0.36 [0.07] cm), no recurrences were found at a median (IQR) follow-up of 4.3 (2.7-6.2) years. During follow-up, 6 patients (1.5%) developed a lesion suspicious for recurrence near the excision scar, which was excised and showed nevus or solar lentigo on histopathology. No patients had metastasis or melanoma-specific death.</p>
<p><strong class="sub-title">Conclusions and relevance: </strong>This cohort study found that diagnostic excisional biopsies with clear margins may be sufficient for treating MIS; however, larger studies are necessary.</p>
</div>
<p>To access the full article <a href="https://pubmed.ncbi.nlm.nih.gov/40900523/" target="_blank" rel="noopener">please click here</a>.</p>
</div>




			</div> 
		</div>
	</div> 
</div></div>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/clinical-workflow-documentation/">CLINICAL WORKFLOW &AMP; DOCUMENTATION</a></li><li><a href="https://molemaxsystems.com/category/dermoscopy-techniques-clinical-studies/">DERMOSCOPY TECHNIQUES &AMP; CLINICAL STUDIES</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/molemax-hd-total-body-mapping/">MOLEMAX HD &AMP; TOTAL BODY MAPPING</a></li><li><a href="https://molemaxsystems.com/category/research-clinical-evidence/">RESEARCH &AMP; CLINICAL EVIDENCE</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-detection-diagnosis/">SKIN CANCER DETECTION &AMP; DIAGNOSIS</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-research-evidence/">SKIN CANCER RESEARCH &AMP; EVIDENCE</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/local-recurrence-and-survival-in-patients-with-melanoma-in-situ/">Local Recurrence and Survival in Patients With Melanoma In Situ</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Mohs Surgery vs Wide Local Excision in Primary High-Stage Cutaneous Squamous Cell Carcinoma</title>
		<link>https://molemaxsystems.com/mohs-surgery-vs-wide-local-excision-in-primary-high-stage-cutaneous-squamous-cell-carcinoma/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Mon, 23 Jun 2025 00:28:45 +0000</pubDate>
				<category><![CDATA[Skin Cancer Detection & Diagnosis]]></category>
		<category><![CDATA[skin cancer]]></category>
		<category><![CDATA[Squamous Cell Carcinoma]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=8058</guid>

					<description><![CDATA[<p>Comparing Mohs surgery and wide local excision outcomes</p>
<p>The post <a href="https://molemaxsystems.com/mohs-surgery-vs-wide-local-excision-in-primary-high-stage-cutaneous-squamous-cell-carcinoma/">Mohs Surgery vs Wide Local Excision in Primary High-Stage Cutaneous Squamous Cell Carcinoma</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p><span class="authors-list-item ">David M Wang<span class="comma">, </span></span><span class="authors-list-item ">Michelangelo Vestita<span class="comma">, </span></span><span class="authors-list-item ">Fadi G Murad<span class="comma">, </span></span><span class="authors-list-item ">Frederick C Morgan<span class="comma">, </span></span><span class="authors-list-item ">Rachael Rowley<span class="comma">, </span></span><span class="authors-list-item ">Eleni M Rettig<span class="comma">, </span></span><span class="authors-list-item ">William Lotter<span class="comma">, </span></span><span class="authors-list-item ">Abigail B Waldman<span class="comma">, </span></span><span class="authors-list-item ">Emily S Ruiz<span class="comma">, </span></span><span class="authors-list-item ">Chrysalyne D Schmults</span></p>
<h2 class="title">Abstract</h2>
<div id="eng-abstract" class="abstract-content selected">
<p><strong class="sub-title">Importance: </strong>High-stage cutaneous squamous cell carcinoma (cSCC) has an increased risk of recurrence, metastasis, and mortality. Studies investigating the outcomes of high-stage cSCC among patients treated with Mohs surgery compared with those treated with wide local excision (WLE) are limited.</p>
<p><strong class="sub-title">Objective: </strong>To assess the outcomes of primary high-stage cSCC among patients treated with Mohs surgery compared with those treated with WLE.</p>
<p><strong class="sub-title">Design, setting, and participants: </strong>This retrospective cohort study using propensity score weighting was conducted in a tertiary academic medical center in Boston, Massachusetts. Patients were included if they had primary high-stage cSCC and had been treated with either Mohs surgery or WLE between January 1, 2000, and December 31, 2019. Data analysis was performed between November 3 and 6, 2023.</p>
<p><strong class="sub-title">Exposures: </strong>Primary surgical treatment with Mohs surgery or WLE.</p>
<p>To read this article further please <a href="https://pubmed.ncbi.nlm.nih.gov/39969890/" target="_blank" rel="noopener">click here</a>.</p>
</div>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/clinical-workflow-documentation/">CLINICAL WORKFLOW &AMP; DOCUMENTATION</a></li><li><a href="https://molemaxsystems.com/category/dermoscopy-techniques-clinical-studies/">DERMOSCOPY TECHNIQUES &AMP; CLINICAL STUDIES</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/molemax-hd-total-body-mapping/">MOLEMAX HD &AMP; TOTAL BODY MAPPING</a></li><li><a href="https://molemaxsystems.com/category/research-clinical-evidence/">RESEARCH &AMP; CLINICAL EVIDENCE</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-detection-diagnosis/">SKIN CANCER DETECTION &AMP; DIAGNOSIS</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-research-evidence/">SKIN CANCER RESEARCH &AMP; EVIDENCE</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/mohs-surgery-vs-wide-local-excision-in-primary-high-stage-cutaneous-squamous-cell-carcinoma/">Mohs Surgery vs Wide Local Excision in Primary High-Stage Cutaneous Squamous Cell Carcinoma</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Subungual Amelanotic Melanoma</title>
		<link>https://molemaxsystems.com/subungual-amelanotic-melanoma/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Thu, 13 Mar 2025 00:09:49 +0000</pubDate>
				<category><![CDATA[Skin Cancer Detection & Diagnosis]]></category>
		<category><![CDATA[dematology research]]></category>
		<category><![CDATA[melanoma]]></category>
		<category><![CDATA[skin cancer]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=7716</guid>

					<description><![CDATA[<p>Understanding subungual amelanotic melanoma diagnosis and detection</p>
<p>The post <a href="https://molemaxsystems.com/subungual-amelanotic-melanoma/">Subungual Amelanotic Melanoma</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p><span class="wi-fullname brand-fg">Xing Fang, MD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Tianjing Gao, MD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Yu Fu, MD</span></p>
<p><span class="drop-cap">A </span>woman in her 60s presented with a 4-year history of separation and rupture of the right fourth fingernail. Initially, she noted that the nail plate had become detached and cracked without any history of trauma, leading to the appearance of a painful ulcer at the root of the nail bed. Six months later, a light pink and porcelain white patch also developed around the nail. The patient initially received a diagnosis of a nail infection and was treated with topical antibiotic ointment at a local hospital, but no improvement was observed. Moreover, a progressively enlarging stringlike mass developed beneath the ruptured nail.</p>
<p>To read the full article please <a href="https://jamanetwork.com/journals/jamadermatology/fullarticle/2830696?guestAccessKey=60e1ab2b-0ef2-4e88-b77b-06d938e64f5a&amp;utm_source=silverchair&amp;utm_medium=email&amp;utm_campaign=article_alert-jamadermatology&amp;utm_content=mostreadwidget&amp;utm_term=031225&amp;adv=000004292862" target="_blank" rel="noopener">click here</a>.</p>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/clinical-workflow-documentation/">CLINICAL WORKFLOW &AMP; DOCUMENTATION</a></li><li><a href="https://molemaxsystems.com/category/dermoscopy-techniques-clinical-studies/">DERMOSCOPY TECHNIQUES &AMP; CLINICAL STUDIES</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/molemax-hd-total-body-mapping/">MOLEMAX HD &AMP; TOTAL BODY MAPPING</a></li><li><a href="https://molemaxsystems.com/category/research-clinical-evidence/">RESEARCH &AMP; CLINICAL EVIDENCE</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-detection-diagnosis/">SKIN CANCER DETECTION &AMP; DIAGNOSIS</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-research-evidence/">SKIN CANCER RESEARCH &AMP; EVIDENCE</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/subungual-amelanotic-melanoma/">Subungual Amelanotic Melanoma</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Skin Cancer Diagnosis by Lesion, Physician, and Examination Type</title>
		<link>https://molemaxsystems.com/skin-cancer-diagnosis-by-lesion-physician-and-examination-type/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Wed, 27 Nov 2024 03:25:09 +0000</pubDate>
				<category><![CDATA[Skin Cancer Detection & Diagnosis]]></category>
		<category><![CDATA[dermatology]]></category>
		<category><![CDATA[skin cancer]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=7501</guid>

					<description><![CDATA[<p>Skin cancer diagnosis accuracy by lesion and examination</p>
<p>The post <a href="https://molemaxsystems.com/skin-cancer-diagnosis-by-lesion-physician-and-examination-type/">Skin Cancer Diagnosis by Lesion, Physician, and Examination Type</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[<h3><strong>A Systematic Review and Meta-Analysis</strong></h3>
<p><span style="color: #000000;"><span class="wi-fullname brand-fg">Jennifer Y. Chen, MD</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Kristen Fernandez, BS</span><span class="al-author-delim">; </span><span class="wi-fullname brand-fg">Raj P. Fadadu, MD, MS</span>; <a class="meta-authors--etal td-u stats-meta-authors--etal" style="color: #000000;">et al</a></span></p>
<p>&nbsp;</p>
<p><strong>Importance</strong>  Skin cancer is the most common cancer in the US; accurate detection can minimize morbidity and mortality.</p>
<p><strong>Objective</strong>  To assess the accuracy of skin cancer diagnosis by lesion type, physician specialty and experience, and physical examination method.</p>
<p><strong>Data Sources</strong>  PubMed, Embase, and Web of Science.</p>
<p><strong>Study Selection</strong>  Cross-sectional and case-control studies, randomized clinical trials, and nonrandomized controlled trials that used dermatologists or primary care physicians (PCPs) to examine keratinocytic and/or melanocytic skin lesions were included.</p>
<p><strong>Data Extraction and Synthesis</strong>  Search terms, study objectives, and protocol methods were defined before study initiation. Data extraction was performed by a reviewer, with verification by a second reviewer. A mixed-effects model was used in the data analysis. Data analyses were performed from May 2022 to December 2023.</p>
<p>To read the full article please <a href="https://jamanetwork.com/journals/jamadermatology/article-abstract/2826310?guestAccessKey=517865e2-dacb-4936-b723-1aaf92171d3a&amp;utm_source=silverchair&amp;utm_medium=email&amp;utm_campaign=article_alert-jamadermatology&amp;utm_content=olf&amp;utm_term=111324&amp;adv=000004292862" target="_blank" rel="noopener">click here</a>.</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/clinical-workflow-documentation/">CLINICAL WORKFLOW &AMP; DOCUMENTATION</a></li><li><a href="https://molemaxsystems.com/category/dermoscopy-techniques-clinical-studies/">DERMOSCOPY TECHNIQUES &AMP; CLINICAL STUDIES</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/molemax-hd-total-body-mapping/">MOLEMAX HD &AMP; TOTAL BODY MAPPING</a></li><li><a href="https://molemaxsystems.com/category/research-clinical-evidence/">RESEARCH &AMP; CLINICAL EVIDENCE</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-detection-diagnosis/">SKIN CANCER DETECTION &AMP; DIAGNOSIS</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-research-evidence/">SKIN CANCER RESEARCH &AMP; EVIDENCE</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/skin-cancer-diagnosis-by-lesion-physician-and-examination-type/">Skin Cancer Diagnosis by Lesion, Physician, and Examination Type</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Actinic Keratosis Today</title>
		<link>https://molemaxsystems.com/actinic-keratosis-today/</link>
		
		<dc:creator><![CDATA[molemax]]></dc:creator>
		<pubDate>Thu, 17 Oct 2024 01:24:36 +0000</pubDate>
				<category><![CDATA[Skin Cancer Detection & Diagnosis]]></category>
		<category><![CDATA[dematology research]]></category>
		<category><![CDATA[skin cancer]]></category>
		<guid isPermaLink="false">https://molemaxsystems.com/?p=7141</guid>

					<description><![CDATA[<p>Understanding actinic keratosis diagnosis, risks, and treatments</p>
<p>The post <a href="https://molemaxsystems.com/actinic-keratosis-today/">Actinic Keratosis Today</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p><strong>Topical Pharmacological Treatment of Actinic Keratoses: Focus on</strong><br />
<strong>Tirbanibulin 1% Ointment</strong><br />
<em>Mario Valenti, Matteo Bianco, Alessandra Narcisi, Antonio Costanzo,</em><br />
<em>Riccardo Borroni, Marco Ardigò</em></p>
<p><strong>Clinical and Dermoscopic Diagnosis of Actinic Keratosis</strong><br />
<em>Claudio Conforti, Luca Ambrosio, Chiara Retrosi, Carmen Cantisani,</em><br />
<em>Giovanni Di Lella, Luca Fania, Roberta Rotunno, Iris Zalaudek, Giovanni</em><br />
<em>Pellacani</em></p>
<p><strong>Epidemiology and Risk Factors of Actinic Keratosis. What Is New for The</strong><br />
<strong>Management for Sun-Damaged Skin</strong><br />
<em>Janis Raphael Thamm, Sandra Schuh, Julia Welzel</em></p>
<p>To read this compilation of actinic keratoses articles please <a href="https://mattiolihealth.com/wp-content/uploads/2024/08/DPCJ-Supplement_2024.pdf" target="_blank" rel="noopener">click here</a>.</p>
<p>&nbsp;</p>
<div class="molemax-categories-injected"><ul class="molemax-cat-list"><li><a href="https://molemaxsystems.com/blog">ALL</a></li><li><a href="https://molemaxsystems.com/category/clinical-workflow-documentation/">CLINICAL WORKFLOW &AMP; DOCUMENTATION</a></li><li><a href="https://molemaxsystems.com/category/dermoscopy-techniques-clinical-studies/">DERMOSCOPY TECHNIQUES &AMP; CLINICAL STUDIES</a></li><li><a href="https://molemaxsystems.com/category/digital-dermoscopy-skin-imaging/">DIGITAL DERMOSCOPY &AMP; SKIN IMAGING</a></li><li><a href="https://molemaxsystems.com/category/evidence-research/">EVIDENCE &AMP; RESEARCH</a></li><li><a href="https://molemaxsystems.com/category/mole-mapping-lesion-tracking/">MOLE MAPPING &AMP; LESION TRACKING</a></li><li><a href="https://molemaxsystems.com/category/molemax-hd-total-body-mapping/">MOLEMAX HD &AMP; TOTAL BODY MAPPING</a></li><li><a href="https://molemaxsystems.com/category/research-clinical-evidence/">RESEARCH &AMP; CLINICAL EVIDENCE</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-detection-diagnosis/">SKIN CANCER DETECTION &AMP; DIAGNOSIS</a></li><li><a href="https://molemaxsystems.com/category/skin-cancer-research-evidence/">SKIN CANCER RESEARCH &AMP; EVIDENCE</a></li></ul></div><p>The post <a href="https://molemaxsystems.com/actinic-keratosis-today/">Actinic Keratosis Today</a> appeared first on <a href="https://molemaxsystems.com">MoleMax Systems</a>.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
